- Home
- ZENV vs LCTX Comparison
ZENV vs LCTX Comparison
Compare ZENV & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- LCTX
- Stock Information
- Founded
- ZENV 2005
- LCTX 1990
- Country
- ZENV Brazil
- LCTX United States
- Employees
- ZENV N/A
- LCTX N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZENV Technology
- LCTX Health Care
- Exchange
- ZENV Nasdaq
- LCTX Nasdaq
- Market Cap
- ZENV 146.3M
- LCTX 127.7M
- IPO Year
- ZENV 2021
- LCTX N/A
- Fundamental
- Price
- ZENV $2.48
- LCTX $0.59
- Analyst Decision
- ZENV
- LCTX Strong Buy
- Analyst Count
- ZENV 0
- LCTX 5
- Target Price
- ZENV N/A
- LCTX $4.80
- AVG Volume (30 Days)
- ZENV 163.3K
- LCTX 2.4M
- Earning Date
- ZENV 11-18-2024
- LCTX 03-06-2025
- Dividend Yield
- ZENV N/A
- LCTX N/A
- EPS Growth
- ZENV N/A
- LCTX N/A
- EPS
- ZENV N/A
- LCTX N/A
- Revenue
- ZENV $173,594,726.00
- LCTX $8,719,000.00
- Revenue This Year
- ZENV $28.66
- LCTX N/A
- Revenue Next Year
- ZENV $2.98
- LCTX $41.15
- P/E Ratio
- ZENV N/A
- LCTX N/A
- Revenue Growth
- ZENV 23.49
- LCTX N/A
- 52 Week Low
- ZENV $1.01
- LCTX $0.48
- 52 Week High
- ZENV $3.88
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- ZENV 58.11
- LCTX 52.01
- Support Level
- ZENV $2.26
- LCTX $0.55
- Resistance Level
- ZENV $2.77
- LCTX $0.60
- Average True Range (ATR)
- ZENV 0.32
- LCTX 0.04
- MACD
- ZENV -0.02
- LCTX 0.01
- Stochastic Oscillator
- ZENV 42.04
- LCTX 83.38
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.